KHIRON LIFE SCIENCES CORP - KHRNF STOCK NEWS

Khiron Life Sciences Corp. (KHRNF) reported impressive financial results for Q1 2022, achieving $4.6 million in revenue, a 65% year-over-year increase. Notably, medical cannabis revenue soared to $2.6 million, up 470% from Q1 2021. Gross profit before fair value adjustments reached $2.1 million, yielding a 96% increase year-over-year. Europe accounted for 53% of medical cannabis revenue, a significant jump from 10% in the previous year. They ended Q1 2022 with $5.1 million in cash, down from $8.6 million in Q1 2021, primarily due to operational expenses.

Khiron Life Sciences Corp. has announced a Conference Call on May 31, 2022, at 10:00 a.m. Eastern time to discuss its first-quarter results for the period ending March 31, 2022. The Company, which operates in Latin America and Europe, will release its financial results prior to the call. Presenters include Alvaro Torres (CEO), Swapan Kakumanu (CFO), and Franziska Katterbach (President of Khiron Europe). Interested participants can register for the call online.

Khiron Life Sciences Corp. has reported a significant milestone, expecting to exceed 1 million CAD in medical cannabis revenues in the UK for Q1 2022. The company has experienced a remarkable sales volume growth of 240% compared to 2021, driven by its UK clinic established in late 2021. Khiron's product portfolio includes KHIRON 20/1, a leading THC-predominant cannabis flower in the UK market. The UK holds a potential of over 1 million medical cannabis patients, presenting extensive opportunities for Khiron to consolidate its market leadership.

Khiron Life Sciences Corp. reported significant growth in its financial results for 2021, with total revenue reaching $12.8 million, a 60% increase year-over-year. Medical cannabis sales accounted for $4.6 million, representing 36% of total revenue. The company forecasts Q1 2022 revenues of approximately $4.5 million. Gross profit soared over 230% YoY to $4.9 million, fueled by the medical cannabis segment. Operations in Germany and the U.K. now represent over 30% of sales, highlighting Khiron's expansion in Europe.

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) will host a conference call on May 2, 2022, at 10:00 a.m. Eastern Time to discuss its financial results for the year and quarter ended December 31, 2021. Prior to the call, Khiron will issue a press release detailing these results, available on their SEDAR profile. The call invites investors, analysts, and advisors to participate, followed by a Q&A session. A replay will be accessible post-call until June 2, 2022.

Khiron Life Sciences Corp. (TSXV:KHRN)(OTCQX:KHRNF) has announced the opening of a new Zerenia clinic and retail pharmacy in Bogota, Colombia. This expansion aims to enhance patient care following the Colombian government's mandate for insurance coverage of medical cannabis products. The new clinic can handle 40,000 consults annually, capitalizing on a market leadership position with Q1 2022 sales volume up 280% year-over-year. The retail pharmacy will offer access to medical cannabis beyond the clinic network, further solidifying Khiron's leadership in the Colombian market.

Khiron Life Sciences Corp. has published groundbreaking results in the Frontiers in Pain Research journal, showcasing its lead position in medical cannabis. In a study involving 2,112 Colombian patients with chronic pain, 90% reported improved pain, 70% noted over a 50% improvement, and only 30% experienced mild side effects. This comprehensive research validates Khiron's THC and CBD oil-based formulations, assuring physicians and insurers of their efficacy and safety. CEO Alvaro Torres emphasized the study's global implications for cannabis-based medications.

Khiron Life Sciences Corp. has partnered with Teleton to enhance access to medical cannabis across Mexico's 24 medical centers. This collaboration includes establishing Zerenia™ medical cannabis clinics, distributing products in Teleton's pharmacies, and training healthcare practitioners.

The partnership aims to serve over 600,000 patients with disabilities, cancer, and autism. Khiron has received regulatory authorization from COFEPRIS for importing CBD and THC, targeting a population of nearly 130 million in Mexico, and is set to begin commercial sales.

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) is a leading medical cannabis company with operations in Latin America and Europe. The company will participate in key investor conferences in March 2022, including the Q1 2022 Virtual Investor Summit from March 8-10, where their presentation is scheduled for March 8 at 9:30 a.m. ET. Additionally, they will present at the OTC Life Sciences Virtual Investor Conference on March 10 at 11:30 a.m. ET, and the 34th Annual Roth Capital Partners Conference from March 13-15 in Dana Point, California.